Vanguard Asset Management
TERN

Vanguard Asset Management’s Terns Pharmaceuticals TERN Stock Holding History

Vanguard Asset Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-37,267
Closed -$1.96M – 2482
2026
Q1 		$1.96M Buy
+37,267
New +$1.53M ﹤0.01% 1473

Other funds holding TERN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vanguard Asset Management's TERN Position: Q2 2026 in Review

Vanguard Asset Management sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 37,267 shares — an estimated $1.96M sold.

Vanguard Asset Management first reported a position in TERN in Q1 2026 and held it in 1 quarter. The position peaked at $1.96M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

  • Vanguard Asset Management reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vanguard Asset Management sold 37,267 Terns Pharmaceuticals shares in Q2 2026, an estimated $1.96M.
  • Vanguard Asset Management first reported a position in Terns Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Vanguard Asset Management's Terns Pharmaceuticals position peaked at $1.96M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.